RESPOND REGISTRY

THE FIRST PROSPECTIVE, LARGE, REAL-WORLD EFFECTIVENESS STUDY FOR PURAPLY® AM

The Real-World Effectiveness Study of PuraPly AM on Wounds (RESPOND) was the first prospective, large (N=307), multicenter (28 sites) cohort study to assess the effectiveness of PuraPly AM in various difficult-to-heal wounds.

In a primarily elderly population with large, deep, refractory wounds of long durations, PuraPly AM showed that 86% of all PuraPly AM-treated wounds demonstrated improvement in the wound bed condition. Also, 41.5% of wounds achieved complete closure at 12 weeks.1

STUDY BACKGROUND

Large, prospective, noninterventional cohort study to assess the effectiveness of PuraPly AM in real-world clinical settings at 28 sites.

The primary endpoints were frequency and time to wound closure, and secondary endpoints were percent reduction in wound area, depth, and volume. Other endpoints included improvement in wound bed condition.

  • Postmarketing, prospective, noninterventional, multicenter cohort study (NCT03286452)
  • Patients received standard of care in addition to PuraPly AM
  • Wounds were cleansed and debrided at initial visit
  • At each study visit, digital photography was used to image the wounds, and data was collected for wound measurements (length, width, and depth)
  • N=307 (67 VLUs, 62 DFUs, 45 pressure ulcers, 54 post-surgical wounds, and 79 other wounds)
  • Mean wound duration at baseline: 96.2 days
  • Mean wound area at baseline: 12.9 cm2
  • Mean wound depth at baseline: 5.2 mm
  • Mean wound volume at baseline: 11.2 cm3
  • Mean number of applications: 5.2; 21.8% of patients received 1 to 2 applications
SEE ALL BASELINE CHARACTERISTICS 

RESULTS

PuraPly AM supported healing in large,* difficult-to-heal wounds

*12.9 cm2 mean wound area at baseline

86%

of all PuraPly AM-treated wounds demonstrated improvement in the wound bed condition:
Icon representing the increased healthy granulation tissue demonstrated in the RESPOND study

INCREASEDHEALTHYGRANULATIONTISSUE

Icon representing the reduced exudate demonstrated in the RESPOND study

REDUCEDEXUDATE

Icon representing the readiness for other advanced skin substitutes demonstrated in the RESPOND study

READINESSFOR OTHERADVANCED SKINSUBSTITUTES

41.5%

CLOSURE RATEAT 12 WEEKSFOR ALL WOUNDS

17 WEEKS

MEDIAN TIMETO CLOSUREFOR ALL WOUNDS

41.5% of PuraPly AM-treated wounds achieved complete wound closure at 12 weeks

SEE FREQUENCY OF WOUND CLOSURE BY WEEK 

The median time to wound closure for all PuraPly AM-treated wounds was 17 weeks

SEE MEDIAN TIME TO WOUND CLOSURE BY TYPE 

For all 307 patients treated with PuraPly AM

81%

of wounds achieved >60% reduction in area*
Icon showing that for wounds that achieved >60% reduction in area, the mean baseline was 12.9 cm3

71%

of wounds achieved >60% reduction in depth*
Icon showing that for wounds that achieved >60% reduction in depth, the mean baseline was 5.2 cm3

85%

of wounds achieved >75% reduction in volume*
Icon showing that for wounds that achieved >75% reduction in volume, the mean baseline was 11.2 cm3
*At 32 weeks.

SUPPORTING HEALING IN STALLED WOUNDS

See how PuraPly AM supported healing in chronic wounds that failed ~2 years of prior therapies, or contact an Organogenesis Tissue Regeneration Specialist to see how PuraPly AM can help your practice.

Contact us

Please refer to the PuraPly AM Instructions for Use and PuraPly XT Instructions for Use for complete prescribing information.

REFERENCE:

  1. Bain MA, et al. J Comp Eff Res. 2020:9(10)691-703. doi:10.2217/cer-2020-0058